Protecting effect of N-acetylcysteine on myocard during CABG

Evaluation of cardioprotective effects of “N-acetylcysteine” to cardioplegia and “glucose-insulin-potassium” during coronary artery bypass grafting in patient candidate for CABG

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211062883N3

Enrollment

Registered

2012-11-30

Start date

2011-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease

Interventions

Intervention 1: Control group: infution of GIK during operation. Intervention 2: Intervention group: injetion of N Acetylcistein with cardiopelagic solution.

Treatment - Drugs

Control group: infution of GIK during operation

Intervention group: injetion of N Acetylcistein with cardiopelagic solution

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who candidate for CABG with EF below 50% at Mazandaran Heart Center Exclusion critera:Valvular heart diseases; renal failure; liver disease; cross clamp time more than 1:30 min & use of intraaotric baloon pomp

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ejection fraction of LV. Timepoint: before operation & 5 day after operation. Method of measurement: echocardiograph.	—

Secondary

Measure	Time frame
Arhythmia. Timepoint: during operation & ICU stay. Method of measurement: monitor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammadreza Habibi

Mazandaran University of Medical Sciences

mohammadreza.habibi@gmail.com+98 15 1222 3023

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026